Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer
Journal of Gynecologic Oncology · 2024
DOI: 10.3802/jgo.2024.35.e83 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Gengwei Huo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Antibodies, Monoclonal, Humanized, Endometrial Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: China anti-cancer association HER2 target Chinese research fund, Tianjin education commission for higher education, China, Tianjin key medical discipline (specialty) construction project.
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVE: This study assessed the cost-effectiveness of atezolizumab in combination with chemotherapy for patients with advanced or recurrent endometrial cancer (EC) from the U.S. payer's perspective. METHODS: A cost-effectiveness study was conducted using a Markov model based on ENGOT-en7/MaNGO/AtTEnd clinical trials. The population consisted of patients with EC, stratified by mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) subgroups. The model simulated patients receiving either atezolizumab plus chemotherapy or chemotherapy alone. Cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) were calculated using a Willingness-to-Pay (WTP) threshold of $150,000/QALY. Sensitivity analyses were performed. RESULTS: Adding atezolizumab to chemotherapy in dMMR EC resulted in an incremental gain of 3.31 QALYs but at an additional cost of $855,042, leading to an ICER of $258,391.07/QALY compared to chemotherapy alone. In pMMR EC, there was a gain of 0.50 QALYs with an additional cost of $140,502, resulting in an ICER of $279,239.72/QALY. The overall ICER for EC was $216,459.34/QALY. Scenario analysis indicated that administering atezolizumab for a maximum of 2 years improved cost-effectiveness in dMMR EC, with an ICER of $70,695.96/QALY falling within the predetermined WTP threshold. CONCLUSION: For patients with advanced or recurrent EC, the combination of atezolizumab and chemotherapy may not prove cost-effective. However, administering atezolizumab for a limited period of maximum 2 years could improve cost-effectiveness in dMMR EC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
- National Clinical Research Center for Cancer, Tianjin, China.
- Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.
- Tianjin's Clinical Research Center for Cancer, Tianjin, China.
- Department of Pharmacy, Jining No.1 people's Hospital, Jining, China.
- Tianjin's Clinical Research Center for Cancer, Tianjin, China. chenpengdoc@sina.com.
ORCID-Profile: Gengwei Huo, Ying Song, Peng Chen
Förderung
- China anti-cancer association HER2 target Chinese research fund
- Tianjin education commission for higher education, China
- Tianjin key medical discipline (specialty) construction project
Zitieren
APA
Huo, G., Song, Y., & Chen, P. (2024). Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e83
Vancouver
Huo G, Song Y, Chen P. Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e83
BibTeX
@article{Huo2024,
author = {Huo, Gengwei and Song, Ying and Chen, Peng},
title = {Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer},
journal = {Journal of Gynecologic Oncology},
year = {2024},
doi = {10.3802/jgo.2024.35.e83}
}
EUVIMED